Twist Bioscience Financial Ratios
NASDAQ: TWSTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
159.78+7.73 (+5.08%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Twist Bioscience ratio analysis
Twist Bioscience earned a net margin of -20.6% in FY 2025, up from -66.7% a year earlier. Gross margin was 50.7% compared with a median of 34.2% over the prior 8 years. Return on equity reached -16.4%, meaning Twist Bioscience generated -0.16 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Twist Bioscience financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 4.93 | 8.03 | 4.70 | 9.33 | 38.47 | 33.63 | 11.37 | — | — |
| Price / book | 3.93 | 5.32 | 1.85 | 2.41 | 8.76 | 9.01 | 4.06 | — | — |
| Gross margin | 50.7% | 42.6% | 36.6% | 41.4% | 39.1% | 31.8% | 12.8% | -26.6% | -123.1% |
| Operating margin | -36.2% | -70.6% | -88.6% | -115.3% | -115.4% | -155.5% | -200.1% | -277.5% | -543.2% |
| Net margin | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | -155.3% | -198.0% | -280.2% | -550.8% |
| Free cash flow margin | -20.1% | -22.1% | -69.5% | -111.1% | -105.3% | -168.8% | -188.8% | -274.7% | -537.7% |
| Return on equity (ROE) | -16.4% | -44.2% | -32.8% | -27.6% | -26.2% | -41.6% | -70.8% | — | — |
| Return on assets (ROA) | -12.1% | -34.0% | -26.4% | -22.7% | -21.7% | -35.1% | -57.6% | -61.5% | — |
| Debt / equity | — | — | — | 0.00 | 0.00 | 0.01 | 0.05 | — | — |
| Current ratio | 3.64 | 4.88 | 5.79 | 6.58 | 8.67 | 9.29 | 5.28 | 5.16 | — |
| Revenue growth | 20.3% | 27.7% | 20.4% | 53.8% | 46.9% | 65.7% | 113.9% | 136.2% | — |